Research Article
Presence and Onset of Chronic Kidney Disease as a Factor Involved in the Poor Prognosis of Patients with Essential Thrombocythemia
Table 3
Univariable and multivariable analyses of predictors of overall survival in patients without chronic kidney disease at the time of ET diagnosis.
| Variables | Univariable | Multivariable | HR | 95% CI | value | HR | 95% CI | value |
| Age ≥60 years | 3.402 | 0.409–28.290 | 0.257 | | | | Gender (male) | 4.027 | 0.776–20.890 | 0.097 | | | | WBC ≥11 × 109/L | 1.370 | 0.304–6.181 | 0.682 | | | | Plt ≥1000 × 109/L | 6.015 | 1.147–31.55 | 0.034 | 2.735 | 0.322–23.210 | 0.357 | CRP ≥0.30 mg/dL | 4.786 | 0.961–23.830 | 0.056 | | | | Uric acid ≥7.0 mg/dL | 2.570 | 0.298–22.180 | 0.391 | | | | JAK2V617F mutation | 1.644 | 0.317–8.519 | 0.554 | | | |
| Chromosome abnormality | All patients with chromosome abnormalities survived | History of thrombosis | 2.750 | 0.613–12.340 | 0.187 | | | | History of hemorrhagic events | 2.493 | 0.290–21.440 | 0.406 | | | | Cardiovascular risk factors | 2.262 | 0.431–11.870 | 0.335 | | | | Splenomegaly | 5.452 | 1.219–24.390 | 0.026 | 2.809 | 0.420–18.780 | 0.287 | Antiplatelet therapy | 0.586 | 0.068–5.071 | 0.627 | | | | Cytoreductive therapy with HU | 0.337 | 0.061–1.843 | 0.209 | | | | Cytoreductive therapy with ANA | 1.459 | 0.267–7.974 | 0.663 | | | | Onset of CKD | 11.550 | 2.074–64.280 | 0.005 | 9.155 | 1.542–54.370 | 0.015 |
|
|
ANA, anagrelide; CI, confidence interval; CKD, chronic kidney disease; ET, essential thrombocythemia; HU, hydroxyurea; HR, hazard ratio. values of <0.05 are highlighted in bold. |